Development of potent antibody drug conjugates against ICAM1+ cancer cells in preclinical models of cholangiocarcinoma

We observed an interesting contradictory phenomenon that ICAM1-Dxd showed a very weak cytotoxicity on CCA cell lines in vitro, whereas it mediates more potent tumor attenuation than ICAM1-MMAE in vivo, suggesting the potency of ICAM1-Dxd may arise from its multifaceted biological activities instead of merely cytotoxicity. To elucidate its underlying biomechanism, we performed a transcriptomic RNA sequencing (RNA-seq) to profile the signaling pathways and key genes affected by ICAM1-Dxd treatment in PDX tumor tissues. Overall design: Comparative gene expression profiling analysis of RNA-seq data for PDX tumor tissues with different treatments (ICAM1-Dxd, ICAM1-MMAE, ICAM1 mAb,PBS)